SCHEMBL9923142

SCHEMBL9923142

O=C(Nc1ccc(-n2ccc3cc(I)ccc3c2=O)c(F)c1)NS(=O)(=O)c1ccc(Cl)s1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
P2RY12 Q9H244 5/20 0.48
FBP1 P09467 1/20 0.38
MAPT P10636 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
F10 P00742 2/20 0.34
KCNA1 Q09470 1/20 0.32
KCNAB1 Q14722 1/20 0.32
IDH1 O75874 1/20 0.32
CASP3 P42574 1/20 0.31
SENP8 Q96LD8 1/20 0.31
SENP7 Q9BQF6 1/20 0.31
SENP6 Q9GZR1 1/20 0.31
CA12 O43570 3/20 0.31
CA9 Q16790 3/20 0.31
CA1 P00915 2/20 0.31
CA2 P00918 2/20 0.31
APP P05067 2/20 0.31
SLC22A12 Q96S37 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12161183 0.92 P2RY12 (0.48) P2RY12FBP1MAPTMEN1KMT2A
SCHEMBL9922112 0.91 P2RY12 (0.53) P2RY12FBP1MAPTMEN1KMT2A
SCHEMBL9923146 0.90 P2RY12 (0.49) P2RY12FBP1MAPTMEN1KMT2A
SCHEMBL9922646 0.89 P2RY12 (0.47) P2RY12FBP1MAPTMEN1KMT2A
SCHEMBL9922638 0.89 P2RY12 (0.47) P2RY12FBP1MAPTMEN1KMT2A
SCHEMBL9923144 0.89 P2RY12 (0.47) P2RY12FBP1MAPTMEN1KMT2A
SCHEMBL9923153 0.88 P2RY12 (0.45) P2RY12FBP1MAPTMEN1KMT2A
SCHEMBL9922670 0.88 P2RY12 (0.47) P2RY12FBP1MAPTMEN1KMT2A
SCHEMBL9922114 0.87 P2RY12 (0.48) P2RY12FBP1MAPTMEN1KMT2A
SCHEMBL9923150 0.87 P2RY12 (0.44) P2RY12FBP1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS TBXA2R, GP6, P2RY6 P2RY12 18/4885FBP1 1579/4885MAPT 4832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.